Ranbaxy spinout gets $6.5M for N.J.-based generics biz
Bionpharma just raised $6.5 million, according to a regulatory filing - on top of about $31 million raised last year.
Federal injunction against Ranbaxy impacts US business, excludes generic Lipitor
Ranbaxy‘s generic pharmaceuticals business in the U.S. has been suspended until it can correct violations at its factories in India and the United States that triggered a federal injunction. Under the terms of a settlement reached with the U.S. Department of Justice, which described its investigation of the company as “groundbreaking,” the company is to […]
The Power of One: Redefining Healthcare with an AI-Driven Unified Platform
In a landscape where complexity has long been the norm, the power of one lies not just in unification, but in intelligence and automation.